MedTech company Qureight has appointed Claus Torp Jensen as the chairperson of the board. Qureight, founded in 2018, aims to enhance the survival rates of patients with complex lung and heart diseases by accelerating drug development in conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension, which currently have limited treatment options and poor survival rates.
Qureight utilizes a cloud platform and AI technology to analyze CT scans, blood biomarkers, and clinical results from patients with various diseases. By incorporating both real-world and clinical trial data, the technology generates models that enable researchers to gain a better understanding of how patients may respond to novel treatments.
Earlier this year, Qureight entered into a significant multi-year strategic collaboration with AstraZeneca. This partnership allows AstraZeneca to leverage Qureight’s proprietary platform and AI technology to conduct research on a range of complex lung diseases, further expanding their knowledge of how patients with rare and complex lung diseases might respond to innovative drugs.
Dr. Claus Torp Jensen, an experienced HealthTech and IT sector professional based in the US, brings his extensive expertise to Qureight as the chief innovation officer and EVP of R&D and technology at Teladoc Health, a leading global provider of telemedicine and virtual healthcare. With previous leadership roles at CVS Health, IBM, Danske Bank, and the Memorial Sloan Kettering Cancer Center, Dr. Jensen will guide Qureight’s strategic direction and support the wider board membership alongside co-founders Dr. Muhunthan Thillai (CEO) and Dr. Alessandro Ruggiero (CSO).
Dr. Jensen will join the existing board members, which include Dr. Thillai, Dr. Ruggiero, Chris Smith of Playfair Capital, James Stearns of CMS Ventures, and Caroline Austin of AstraZeneca.
Speaking about his new role, Dr. Jensen said, “Accelerating clinical trials is a major need across all of healthcare. I was attracted to working with the Qureight team because of the way they combine sophisticated technology and clinical expertise to help drive such acceleration while maintaining the overall quality of the trials themselves. Solving this problem, and solving it well, is in high demand across the healthcare and life sciences sector. I look forward to collaborating with the senior leadership team and the other Board members to accelerate Qureight’s growth over the months to come.”
Dr. Thillai expressed his confidence in Dr. Jensen’s appointment, stating that his deep understanding of healthcare data and infrastructure, gained from previous roles at IBM and CVS Health, makes him an ideal chairperson for Qureight. Dr. Thillai further emphasized the importance of Dr. Jensen’s guidance as Qureight integrates real-time data from phase 2 clinical studies starting in the USA, as well as scaling the platform through major industry partnerships.
Overall, Qureight is poised for continued growth and advancement in its mission to improve patient outcomes and revolutionize drug development in the field of MedTech.